<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cryopyrin-associated periodic syndromes and related disorders</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cryopyrin-associated periodic syndromes and related disorders</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cryopyrin-associated periodic syndromes and related disorders</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Nigrovic, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Three clinically overlapping interleukin (IL) 1-associated autoinflammatory disorders are known collectively as the cryopyrin-associated periodic syndromes (CAPS) or cryopyrinopathies: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disorder (NOMID, also known as chronic infantile neurologic cutaneous and articular [CINCA] syndrome). The cryopyrinopathies are rare, with an estimated prevalence of 1 in 360,000 in a French study [<a href="#rid1">1</a>]. A related but distinct autoinflammatory disorder is due to deficiency of the IL-1 receptor antagonist (DIRA).</p><p>There are multiple other autoinflammatory disorders that present with periodic fever. These disorders are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES</span></p><p class="headingAnchor" id="H3"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>All three cryopyrinopathies arise from pathogenic variants in a single gene, <em>NLRP3</em>, at chromosome 1q44, encoding a protein called cryopyrin (also known as nacht domain-, leucine-rich repeat- and pyrin domain-containing protein 3 [NALP3] or pyrin domain-containing apoptotic protease activating factor 1-like protein [PYPAF1]; cryopyrin is derived from the Greek words for icy cold and fire) [<a href="#rid2">2,3</a>]. The mode of inheritance is autosomal dominant with variable penetrance.</p><p class="headingAnchor" id="H4"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Cryopyrin is important in innate immunity as part of the multiprotein NALP3 inflammasome complex [<a href="#rid4">4</a>]. It belongs to a family of nucleotide-binding domain and leucine-rich repeat-containing (NLR) proteins that respond to intracellular pathogens and other danger signals.</p><p>Cryopyrin serves as a scaffold for assembly of the NALP3 inflammasome, one of multiple distinct inflammasome complexes with distinct triggering mechanisms but shared downstream effector function [<a href="#rid4">4</a>]. These inflammasomes are responsible, through a cascade of interactions involving caspase 1, for activation of the potent proinflammatory cytokines interleukin (IL) 1 beta and IL-18 by cleavage of their inactive precursors. The inflammasome also cleaves and activates a protein called "gasdermin D" that forms pores in the cell membrane to enable release of these cytokines into the environment and, under some conditions, also to trigger a form of cell death termed "pyroptosis" [<a href="#rid4">4,5</a>]. In addition to its intracellular function, the NALP3 inflammasome can be released from activated macrophages, where it can amplify inflammation by continuing to activate IL-1-beta in the extracellular milieu and in neighboring phagocytes [<a href="#rid6">6,7</a>].</p><p>Signals for cryopyrin activation include the various pathogen-associated molecular patterns (PAMPs; such as bacterial toxins and viral ribonucleic acid [RNA]); danger-associated molecular patterns (DAMPs; such as uric acid crystals, adenosine triphosphate [ATP], low intracellular concentrations of potassium, skin irritants, ultraviolet B radiation); and alum, the commonly used vaccine adjuvant [<a href="#rid4">4,8,9</a>].</p><p>Point mutations in <em>NLRP3</em> in the cryopyrinopathies are thought to promote aberrant formation of the inflammasome and inappropriate production of active IL-1 beta, either due to defective self-inhibition by the mutant cryopyrin protein or to resistance of the established inflammasome to negative regulatory signals [<a href="#rid10">10-12</a>]. Murine studies suggest that aberrant production of IL-18 and caspase 1-driven pyroptosis plays roles in these diseases, although the efficacy of IL-1 antagonists in patients with CAPS suggests that excess IL-1 beta retains a primary pathogenic role [<a href="#rid13">13</a>]. (See <a class="local">'Treatment of cryopyrinopathies'</a> below.)</p><p>Phenotypic differences among the CAPS probably reflect in large part the differential impact of mutations on the activity of the inflammasome, modulated by individual genetic background. Not surprisingly, the boundaries among these three syndromes are not sharp, and patients may have features of more than one disorder or may not be classic for any of them [<a href="#rid10">10,14,15</a>].</p><p class="headingAnchor" id="H374439414"><span class="h2">Clinical features of specific disorders</span><span class="headingEndMark"> — </span>The clinical features of the three types of CAPS are reviewed below.</p><p class="headingAnchor" id="H5"><span class="h3">Familial cold autoinflammatory syndrome</span><span class="headingEndMark"> — </span>Familial cold autoinflammatory syndrome (FCAS), formerly called familial cold urticaria, is the mildest of the cryopyrin-associated disorders. It is an unusual condition in which exposure to generalized cold, such as an air-conditioned room, results in a stereotyped systemic inflammatory response including fever, an urticarial rash, conjunctival injection, and substantial arthralgias (<a class="graphic graphic_picture graphicRef119818" href="/z/d/graphic/119818.html" rel="external">picture 1</a>).</p><p>Symptoms usually develop in the first year of life, occasionally in the newborn period upon exposure to cold in the delivery room. Urticaria followed by fever starts approximately seven hours after cold exposure. Leukocytosis, sometimes to above 30,000 cells/microL, starts approximately 10 hours after cold exposure and begins to subside 12 to 14 hours later [<a href="#rid16">16,17</a>].</p><p>Attacks usually resolve within 24 hours, though considerable variability is observed between individuals and also depends on the extent and duration of cold exposure. The presence of conjunctivitis and triggering by cold help to discriminate FCAS from other periodic fever disorders [<a href="#rid18">18</a>]. Patients may experience daily rashes, fatigue, headache, and myalgias, particularly toward afternoon and evening, even in the absence of cold exposure.</p><p>Histologically, the rash in these patients is characterized by a marked infiltration of neutrophils, in contrast to other causes of urticaria. (See  <a class="medical medical_review" href="/z/d/html/8108.html" rel="external">"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history"</a>.)</p><p>Uncommonly, chronic untreated FCAS leads to secondary amyloidosis [<a href="#rid19">19-21</a>]. Treatment of FCAS and other cryopyrinopathies is discussed below. (See <a class="local">'Treatment of cryopyrinopathies'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h3">Muckle-Wells syndrome</span><span class="headingEndMark"> — </span>Muckle-Wells syndrome (MWS) is a rare condition characterized by the following triad [<a href="#rid2">2,19,22,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intermittent episodes of fever, headache, urticarial rash, and joint pain (arthralgias or arthritis)</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive sensorineural hearing loss</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary (AA) amyloidosis with nephropathy</p><p></p><p>Febrile episodes occur at irregular intervals every few weeks, lasting 12 to 36 hours before resolving spontaneously. Age of onset is variable. Precipitating factors vary and cannot always be identified, but they may include both heat and cold [<a href="#rid22">22,23</a>]. The sensorineural hearing loss, presumably related to inflammation within the cochlea or the leptomeninges, begins in childhood and may be profound [<a href="#rid24">24-26</a>].</p><p>Amyloidosis occurs in a subset of patients [<a href="#rid19">19,21,27,28</a>]. The signs and symptoms of amyloidosis in the cryopyrinopathies are similar to those observed with secondary amyloidosis in other disorders. (See  <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">"Overview of amyloidosis", section on 'Clinical manifestations'</a>.)</p><p><em>NLRP3</em> pathogenic variants implicated in MWS may be distinct or overlap those causing FCAS [<a href="#rid14">14</a>]. (See <a class="local">'Familial cold autoinflammatory syndrome'</a> above.)</p><p class="headingAnchor" id="H7"><span class="h3">Neonatal-onset multisystem inflammatory disease</span><span class="headingEndMark"> — </span>Neonatal-onset multisystem inflammatory disorder (NOMID), also known as chronic infantile neurologic cutaneous and articular (CINCA) syndrome, is the most severe of the autoinflammatory cryopyrinopathies [<a href="#rid10">10,29</a>].</p><p>Clinical features, including a migratory, erythematous rash resembling urticaria, fever, impaired growth, abnormal facies with frontal bossing, protruding eyes, and saddle-shaped nose, are characteristic and generally develop at or near the time of birth [<a href="#rid14">14</a>]. Other manifestations are chronic meningitis, sensorineural hearing loss, cerebral atrophy, uveitis, lymphadenopathy, and hepatosplenomegaly [<a href="#rid26">26</a>]. Limb and joint pain is common, and focal exuberant cartilaginous proliferation at growth plates and epiphyses resemble tumors. NOMID may cause premature death, and chronic inflammation may lead to secondary amyloidosis. Images and links to additional images of the rash and other findings associated with these conditions can be found on the website of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fautoinflammatory.org%2F&amp;token=EKEpN9bzKYOg002Mef0iMRPyHh5kZSevJxuxxrXshrVg50zT4XsFAiv8pNB4SIP5&amp;TOPIC_ID=5585" target="_blank">Autoinflammatory Alliance</a>.</p><p class="headingAnchor" id="H15076366"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis should be suspected in patients with recurrent episodes of unexplained systemic inflammation, with fever present in most, but not all, patients. Urticaria is a hallmark manifestation that occurs in almost all patients and rarely in other autoinflammatory syndromes. Sensorineural hearing loss is also essentially restricted to CAPS among the autoinflammatory disorders [<a href="#rid18">18</a>]. A family history is common since these diseases are autosomal dominant, but sporadic cases may occur.</p><p>Diagnostic criteria include raised inflammatory markers (C-reactive protein [CRP] and serum amyloid A) plus at least two of six typical CAPS manifestations [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Urticaria-like rash</p><p class="bulletIndent1"><span class="glyph">●</span>Cold-triggered episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Sensorineural hearing loss</p><p class="bulletIndent1"><span class="glyph">●</span>Musculoskeletal symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic aseptic meningitis</p><p class="bulletIndent1"><span class="glyph">●</span>Skeletal abnormalities</p><p></p><p>The diagnosis of CAPS is confirmed by genetic testing for <em>NALP3</em> mutations. In an analysis of over 800 samples sent for <em>NALP3</em> mutation testing, a positive test was unlikely in a patient with fewer than three episodes, age at presentation ≥20 years, and normal CRP levels [<a href="#rid1">1</a>]. Patients with low-penetrance <em>NALP3</em> variants (Q703K, R488K, V198M) may present atypically [<a href="#rid31">31</a>]. Some CAPS patients may appear negative for <em>NALP3</em> mutation on conventional testing but are found to exhibit somatic mosaicism for a pathogenic variant using next-generation sequencing, which has superior ability to detect mosaicism compared with conventional Sanger sequencing [<a href="#rid32">32-34</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Treatment of cryopyrinopathies</span><span class="headingEndMark"> — </span>A central role for IL-1 beta in these disorders is confirmed by the effectiveness of therapies directed against IL-1 in preventing and alleviating symptoms and substantially reducing levels of inflammatory indices, including serum amyloid A and associated risk of amyloidosis [<a href="#rid35">35,36</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p class="headingAnchor" id="H9"><span class="h3">Anakinra</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">Anakinra</a> (starting dose 1 to 2 mg/kg daily, typical maximum dose 8 mg/kg daily, given subcutaneously), an IL-1 receptor antagonist, is approved by the US Food and Drug Administration (FDA) for treatment of NOMID [<a href="#rid37">37</a>]. It is also used for other forms of CAPS (FCAS and MWS) and for deficiency of the IL-1 receptor antagonist (DIRA). (See <a class="local">'Deficiency of the IL-1-receptor antagonist (DIRA)'</a> below.)</p><p>In patients with FCAS, treatment with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> can prevent cold-induced attacks and markedly reduce daily symptoms [<a href="#rid38">38-40</a>]. Among patients with renal secondary amyloidosis due to CAPS, anakinra has led to marked reductions in proteinuria and stabilization of serum creatinine [<a href="#rid20">20,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">"Renal amyloidosis"</a>.)</p><p>Treatment with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> can also control systemic inflammation in MWS, potentially with an effect on amyloid risk mediated through normalization of levels of serum amyloid A protein. The impact on hearing loss remains uncertain, but partial recovery has been reported [<a href="#rid23">23,41-44</a>]. Measurement of intrathecal inflammatory markers suggests that anakinra may be superior to the monoclonal anti-IL-1 beta <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> (see <a class="local">'Canakinumab'</a> below) for control of central nervous system (CNS) inflammation given its ability to penetrate the blood-brain barrier [<a href="#rid45">45</a>].</p><p>In NOMID/CINCA, treatment with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> has improved signs and symptoms related to inflammation in some [<a href="#rid46">46-51</a>], but not all [<a href="#rid49">49</a>], cases. Bone and joint abnormalities are less responsive to this agent [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Rilonacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">Rilonacept</a> (given subcutaneously, loading dose 4.4 mg/kg, maximum dose 320 mg; weekly maintenance dose 2.2 mg/kg, maximum dose 160 mg), an IL-1 trap, is approved by the US FDA for treatment of patients 12 years of age and older with CAPS, including FCAS and MWS [<a href="#rid52">52</a>]. Treatment with rilonacept can markedly reduce symptoms and inflammatory markers, including serum CRP and serum amyloid A [<a href="#rid53">53,54</a>]. Two double-blind, placebo-controlled trials of 6 and 18 weeks duration examined the effects of rilonacept in 41 patients with FCAS and 3 with MWS. The treated patients experienced a significant reduction in symptom scores compared with placebo (84 versus 13 percent) [<a href="#rid54">54</a>]. The drug was well tolerated, and the most common adverse effects were injection-site reactions (36 versus 13 percent).</p><p class="headingAnchor" id="H11"><span class="h3">Canakinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">Canakinumab</a> is a human anti-IL-1 beta monoclonal antibody that does not react with other members of the IL-1 family. Subcutaneous administration of canakinumab to 35 patients with CAPS resulted in a complete response in 34 [<a href="#rid55">55</a>]. Of the responders, 31 were randomly assigned to receive canakinumab or placebo every 8 weeks for up to 24 weeks. Treated patients were more likely to remain in remission (100 versus 19 percent) and to normalize their serum CRP and serum amyloid A protein levels.</p><p>Benefit was sustained in an open-label extension. The median time to flare in the placebo-treated patients was approximately 22 weeks after the initial dose of <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> given prior to randomization. The incidence of suspected infections was significantly higher in the canakinumab-treated patients during the randomized phase of the trial (67 versus 25 percent) [<a href="#rid55">55</a>]. Follow-up data as long as six years support the safety of canakinumab in CAPS patients [<a href="#rid56">56</a>].</p><p>Clinical response may be less complete in patients with the most severe cryopyrinopathy, NOMID, despite dose escalation to 8 mg/kg every four weeks, which is double the conventional dose [<a href="#rid57">57</a>]. In addition, studies of cerebrospinal fluid (CSF) showed that <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> was not as effective as <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> at reducing leukocyte counts and cytokine levels, potentially because of the superior CSF penetration of anakinra, suggesting that the latter may be preferable for the treatment of CNS inflammation in NOMID [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Case reports suggest that other drugs may be effective in patients with NOMID/CINCA, including <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid58">58</a>] and the anti-IL-6 receptor antibody, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid49">49</a>]. In one case, a patient with CAPS and coincident leukemia exhibited resolution of her CAPS following allogenic hematopoietic cell transplantation [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1145551345"><span class="h3">Vaccination in CAPS</span><span class="headingEndMark"> — </span>Exacerbations of inflammation in CAPS have been reported following vaccination against pneumococcus with either the polysaccharide or the conjugate vaccine [<a href="#rid60">60,61</a>]. Flare of disease has also been reported after vaccination against <em>Neisseria meningitidis</em> (meningococcus) [<a href="#rid62">62</a>]. The benefit of this vaccination must therefore be balanced against the risk in this population.</p><p class="headingAnchor" id="H1310990884"><span class="h1">KERATOENDOTHELIITIS FUGAX HEREDITARIA</span><span class="headingEndMark"> — </span>Patients with this rare condition exhibit repeated attacks of unilateral conjunctival injection, photophobia, and pain, typically one to six times per year, sometimes resulting in corneal scarring [<a href="#rid63">63</a>]. Topic corticosteroid therapy is typically sufficient for control. No other organ systems are involved. This condition segregates with a variant in <em>NLRP3</em>, c.61G&gt;C and appears to be a mild focal cryopyrinopathy [<a href="#rid63">63,64</a>].</p><p class="headingAnchor" id="H13"><span class="h1">DEFICIENCY OF THE IL-1-RECEPTOR ANTAGONIST (DIRA)</span></p><p class="headingAnchor" id="H14"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>An autoinflammatory syndrome distinct from the cryopyrinopathies is characterized by the neonatal onset of sterile multifocal osteomyelitis, periostitis, and a neutrophilic pustulosis [<a href="#rid65">65-67</a>]. The disease presents at birth or within two months postpartum. Other clinical findings include periarticular swelling from epiphyseal overgrowth, oral mucosal lesions, and vasculitis. Untreated patients may die from multiorgan failure. Marked elevations of the erythrocyte sedimentation rate and serum C-reactive protein (CRP) are present, but fever is not.</p><p class="headingAnchor" id="H15"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The 10 patients described in the two initial reports all exhibited deficiency of the interleukin (IL) 1-receptor antagonist (IL-1RN) due to homozygous germline pathogenic variants in <em>IL1RN</em> [<a href="#rid65">65,66</a>]. Eight of these patients had single point mutations, and two had deletions within the sequence encoding IL-1RN. Two additional patients, both Puerto Rican, were reported with a homozygous microdeletion of <em>IL1RN</em> and five adjacent, related genes, a deletion common in this population [<a href="#rid67">67,68</a>]. The clinical syndrome is thought to be due to hyperresponsiveness to IL-1 beta stimulation because of failure of the defective protein to be secreted. Heterozygous carriers are asymptomatic.</p><p class="headingAnchor" id="H24190861"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is made by genetic testing for mutations involving <em>IL1RN</em>. The differential diagnosis includes infantile pustulosis (neonatal-onset pustulosis), infantile pustular psoriasis, and SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome [<a href="#rid67">67-69</a>]. (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment with nonsteroidal antiinflammatory drugs, disease-modifying antirheumatic drugs, and glucocorticoids was only partially effective. IL-1 inhibitors including <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, a recombinant human IL-1 receptor antagonist, and <a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a>, an IL-1 trap, are approved by the US Food and Drug Administration (FDA) for treatment of DIRA [<a href="#rid37">37,52</a>]. As expected from the pathophysiology, anakinra was highly effective in most patients, with complete resolution of symptoms and skin and bone lesions in small case series [<a href="#rid65">65,66,68</a>]. In a study of six children who had responded to anakinra and were switched to rilonacept (2.2 mg/kg subcutaneously weekly), five had recurrence of micropustular rash during the first three months of the study and underwent dose escalation (4.4 mg/kg weekly), and one patient remained on the starting dose [<a href="#rid70">70</a>]. All patients were in remission at six months and remained in remission for the duration of the two-year study. Growth was normal, quality-of-life scores improved, and no serious adverse events were reported.</p><p class="headingAnchor" id="H281165075"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of CAPS</strong> – Three clinically overlapping autoinflammatory disorders are known collectively as the cryopyrin-associated periodic syndromes (CAPS) or cryopyrinopathies: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disorder (NOMID, also known as chronic infantile neurologic cutaneous and articular [CINCA] syndrome). (See <a class="local">'Introduction'</a> above and <a class="local">'Cryopyrin-associated periodic syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics and pathogenesis</strong> – The CAPS all arise from point mutations in a single gene, <em>NLRP3</em> (nacht domain-, leucine-rich repeat- and pyrin domain-containing protein 3 [NALP3]), which encodes the cryopyrin protein. Cryopyrin is important in innate immunity as part of the multiprotein inflammasome complex. Inheritance of these disorders is autosomal dominant with variable penetrance. <em>NLRP3</em> mutations promote aberrant formation of the inflammasome and inappropriate production of active interleukin (IL) 1 beta. Phenotypic differences among CAPS are thought to largely reflect the differential impact of mutations on the activity of the inflammasome, modulated by individual genetic background. The syndromes may overlap, and patients may have features of more than one disorder. (See <a class="local">'Genetics'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Familial cold autoinflammatory syndrome</strong> – FCAS, formerly called familial cold urticaria, is the mildest of the cryopyrin-associated disorders. It is an unusual condition in which exposure to generalized cold, such as an air-conditioned room, results in a stereotyped systemic inflammatory response including fever, an urticarial rash, conjunctival injection, and substantial arthralgias. Symptoms usually develop in the first year of life. Attacks usually resolve within 24 hours, though considerable variability is observed. The presence of conjunctivitis helps to discriminate FCAS from other periodic fever disorders. (See <a class="local">'Familial cold autoinflammatory syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muckle-Wells syndrome</strong> – MWS is a rare condition characterized by the triad of intermittent episodes of fever, headache, urticarial rash, and joint pain (arthralgias or arthritis); progressive sensorineural hearing loss; and secondary amyloidosis with nephropathy. Febrile episodes occur at irregular intervals every few weeks, lasting 12 to 36 hours before resolving spontaneously. Age of onset is variable. Precipitating factors vary and cannot always be identified, but they may include both heat and cold. (See <a class="local">'Muckle-Wells syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal-onset multisystem inflammatory disorder</strong> – Abnormalities in cryopyrin are responsible for NOMID, which is also known as CINCA syndrome. Clinical features, including a migratory, erythematous rash resembling urticaria, fever, impaired growth, abnormal facies with frontal bossing, protruding eyes, and saddle-shaped nose, are characteristic and generally develop at or near the time of birth. Other manifestations affecting the brain, eyes, joints, liver, and spleen may also be present, and AA amyloidosis can occur. NOMID may cause premature death. (See <a class="local">'Neonatal-onset multisystem inflammatory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – A central role for IL-1 beta in these disorders is confirmed by the effectiveness of therapies directed against IL-1 in preventing and alleviating symptoms and in substantially reducing levels of inflammatory indices, including serum amyloid A. These therapies include <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="9483" href="/z/d/drug information/9483.html" rel="external">rilonacept</a>, and <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a>. Anakinra may be superior to the other agents for central nervous system (CNS) inflammation. Vaccination against pneumococcus should be pursued with caution because of the potential for increased CAPS-associated inflammatory response. (See <a class="local">'Treatment of cryopyrinopathies'</a> above and <a class="local">'Anakinra'</a> above and <a class="local">'Rilonacept'</a> above and <a class="local">'Canakinumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficiency of the IL-1RN (DIRA), a related disorder</strong> – An autoinflammatory syndrome distinct from the cryopyrinopathies is characterized by the neonatal onset of sterile multifocal osteomyelitis, periostitis, a neutrophilic dermatosis, and elevated acute-phase reactants without fever. Untreated patients may die from multiorgan failure. The patients have a deficiency of the IL-1-receptor antagonist (IL-1RN) due to homozygous germline mutations, which may result in hyperresponsiveness to IL-1-beta stimulation and the clinical syndrome. The most effective treatment has been with the IL-1 receptor antagonist, <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>. (See <a class="local">'Deficiency of the IL-1-receptor antagonist (DIRA)'</a> above and <a class="local">'Clinical presentation'</a> above and <a class="local">'Genetics'</a> above and <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1844517704"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011; 70:495.</a></li><li><a class="nounderline abstract_t">Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301.</a></li><li><a class="nounderline abstract_t">Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 2017; 18:832.</a></li><li><a class="nounderline abstract_t">Mathur A, Hayward JA, Man SM. Molecular mechanisms of inflammasome signaling. J Leukoc Biol 2018; 103:233.</a></li><li><a class="nounderline abstract_t">Jorgensen I, Zhang Y, Krantz BA, Miao EA. Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J Exp Med 2016; 213:2113.</a></li><li><a class="nounderline abstract_t">Franklin BS, Bossaller L, De Nardo D, et al. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation. Nat Immunol 2014; 15:727.</a></li><li><a class="nounderline abstract_t">Baroja-Mazo A, Martín-Sánchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 2014; 15:738.</a></li><li><a class="nounderline abstract_t">Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122.</a></li><li><a class="nounderline abstract_t">He Y, Hara H, Núñez G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci 2016; 41:1012.</a></li><li><a class="nounderline abstract_t">Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56:1273.</a></li><li><a class="nounderline abstract_t">Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat Immunol 2016; 17:1176.</a></li><li><a class="nounderline abstract_t">Swanson KV, Ting JP. Reining in uncontrolled inflammasome with PKA. Nat Immunol 2016; 17:1137.</a></li><li><a class="nounderline abstract_t">Brydges SD, Broderick L, McGeough MD, et al. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 2013; 123:4695.</a></li><li><a class="nounderline abstract_t">Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15:61.</a></li><li><a class="nounderline abstract_t">Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015; 74:2043.</a></li><li><a class="nounderline abstract_t">Tindall JP, Beeker SK, Rosse WF. Familial cold urticaria. A generalized reaction involving leukocytosis. Arch Intern Med 1969; 124:129.</a></li><li><a class="nounderline abstract_t">Doeglas HM, Bleumink E. Familial cold urticaria. Clinical findings. Arch Dermatol 1974; 110:382.</a></li><li><a class="nounderline abstract_t">Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015; 74:799.</a></li><li><a class="nounderline abstract_t">Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445.</a></li><li><a class="nounderline abstract_t">Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007; 49:477.</a></li><li><a class="nounderline abstract_t">van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.</a></li><li><a class="nounderline abstract_t">MUCKLE TJ, WELLSM . Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962; 31:235.</a></li><li><a class="nounderline abstract_t">Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607.</a></li><li><a class="nounderline abstract_t">Muckle TJ. The 'Muckle-Wells' syndrome. Br J Dermatol 1979; 100:87.</a></li><li><a class="nounderline abstract_t">Montealegre Sanchez GA, Hashkes PJ. Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes. Dev Med Child Neurol 2009; 51:420.</a></li><li><a class="nounderline abstract_t">Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol Head Neck Surg 2011; 145:295.</a></li><li><a class="nounderline abstract_t">Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004; 5:289.</a></li><li><a class="nounderline abstract_t">Dodé C, Cuisset L, Delpech M, Grateau G. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis. J Nephrol 2003; 16:435.</a></li><li><a class="nounderline abstract_t">Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46:3340.</a></li><li><a class="nounderline abstract_t">Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 2017; 76:942.</a></li><li><a class="nounderline abstract_t">Kuemmerle-Deschner JB, Verma D, Endres T, et al. Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges. Arthritis Rheumatol 2017; 69:2233.</a></li><li><a class="nounderline abstract_t">Nakagawa K, Gonzalez-Roca E, Souto A, et al. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Ann Rheum Dis 2015; 74:603.</a></li><li><a class="nounderline abstract_t">Omoyinmi E, Melo Gomes S, Standing A, et al. Brief Report: whole-exome sequencing revealing somatic NLRP3 mosaicism in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheumatol 2014; 66:197.</a></li><li><a class="nounderline abstract_t">Lasigliè D, Mensa-Vilaro A, Ferrera D, et al. Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization. J Rheumatol 2017; 44:1667.</a></li><li><a class="nounderline abstract_t">ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015; 74:1636.</a></li><li><a class="nounderline abstract_t">Rodrigues F, Cuisset L, Cador-Rousseau B, et al. AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. Rheumatology (Oxford) 2022; 61:4827.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103950s5189lbl.pdf.</li><li><a class="nounderline abstract_t">Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 2008; 47:309.</a></li><li><a class="nounderline abstract_t">Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779.</a></li><li><a class="nounderline abstract_t">Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142:1591.</a></li><li><a class="nounderline abstract_t">Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348:2583.</a></li><li><a class="nounderline abstract_t">Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.</a></li><li><a class="nounderline abstract_t">Mirault T, Launay D, Cuisset L, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006; 54:1697.</a></li><li><a class="nounderline abstract_t">Yamazaki T, Masumoto J, Agematsu K, et al. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 2008; 58:864.</a></li><li><a class="nounderline abstract_t">Rodriguez-Smith J, Lin YC, Tsai WL, et al. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis Rheumatol 2017; 69:1325.</a></li><li><a class="nounderline abstract_t">Matsubayashi T, Sugiura H, Arai T, et al. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr 2006; 95:246.</a></li><li><a class="nounderline abstract_t">Seitz M, Kamgang RK, Simon HU, Villiger PM. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Ann Rheum Dis 2005; 64:1802.</a></li><li><a class="nounderline abstract_t">Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 2005; 44:689.</a></li><li><a class="nounderline abstract_t">Matsubara T, Hasegawa M, Shiraishi M, et al. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. Arthritis Rheum 2006; 54:2314.</a></li><li><a class="nounderline abstract_t">Caroli F, Pontillo A, D'Osualdo A, et al. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2007; 46:473.</a></li><li><a class="nounderline abstract_t">Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125249s047lbl.pdf.</li><li><a class="nounderline abstract_t">Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432.</a></li><li><a class="nounderline abstract_t">Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443.</a></li><li><a class="nounderline abstract_t">Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416.</a></li><li><a class="nounderline abstract_t">Walker UA, Tilson HH, Hawkins PN, et al. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. RMD Open 2021; 7.</a></li><li><a class="nounderline abstract_t">Sibley CH, Chioato A, Felix S, et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis 2015; 74:1714.</a></li><li><a class="nounderline abstract_t">Kallinich T, Hoffman HM, Roth J, Keitzer R. The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand J Rheumatol 2005; 34:246.</a></li><li><a class="nounderline abstract_t">Mori T, Saburi M, Hagihara M, et al. Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis 2021; 80:542.</a></li><li><a class="nounderline abstract_t">Walker UA, Hoffman HM, Williams R, et al. Brief Report: Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin-Associated Periodic Syndromes. Arthritis Rheumatol 2016; 68:516.</a></li><li><a class="nounderline abstract_t">Jaeger VK, Hoffman HM, van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford) 2017; 56:1484.</a></li><li><a class="nounderline abstract_t">Walker UA, Luetke Volksbeck S, Kuemmerle-Deschner J. Flare of a Cryopyrin-associated Periodic Syndrome Following Vaccination with Neisseria Meningitidis Polysaccharides. J Rheumatol 2018; 45:878.</a></li><li><a class="nounderline abstract_t">Turunen JA, Wedenoja J, Repo P, et al. Keratoendotheliitis Fugax Hereditaria: A Novel Cryopyrin-Associated Periodic Syndrome Caused by a Mutation in the Nucleotide-Binding Domain, Leucine-Rich Repeat Family, Pyrin Domain-Containing 3 (NLRP3) Gene. Am J Ophthalmol 2018; 188:41.</a></li><li><a class="nounderline abstract_t">Immonen AT, Kawan S, Vesaluoma M, et al. Clinical Spectrum and Geographic Distribution of Keratitis Fugax Hereditaria Caused by the Pathogenic Variant c.61G&gt;C in NLRP3. Am J Ophthalmol 2022; 236:309.</a></li><li><a class="nounderline abstract_t">Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426.</a></li><li><a class="nounderline abstract_t">Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360:2438.</a></li><li><a class="nounderline abstract_t">Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol 2012; 148:747.</a></li><li><a class="nounderline abstract_t">Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol 2012; 148:301.</a></li><li><a class="nounderline abstract_t">Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name? Arch Dermatol 2012; 148:381.</a></li><li><a class="nounderline abstract_t">Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight 2017; 2.</a></li></ol></div><div id="topicVersionRevision">Topic 5585 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109514" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687797" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28722725" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28855232" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular mechanisms of inflammasome signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27573815" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24952505" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24952504" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496530" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27669650" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mechanism and Regulation of NLRP3 Inflammasome Activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393462" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27548431" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27648539" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Reining in uncontrolled inflammasome with PKA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084736" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12496512" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038238" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5797070" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Familial cold urticaria. A generalized reaction involving leukocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4141601" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Familial cold urticaria. Clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637003" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355493" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336710" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284730" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hereditary periodic fever and reactive amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14476827" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872505" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/427013" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The 'Muckle-Wells' syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563585" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493283" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071491" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12832748" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12483741" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27707729" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28692792" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24326009" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24431285" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Brief Report: whole-exome sequencing revealing somatic NLRP3 mosaicism in a patient with chronic infantile neurologic, cutaneous, articular syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28916543" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26109736" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Recommendations for the management of autoinflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35262642" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35262642" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174231" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541451" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178985" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815153" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454373" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16646042" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18311804" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28118536" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449034" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16284353" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671048" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16802372" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16920754" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical and genetic characterization of Italian patients affected by CINCA syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899778" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899778" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668591" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668535" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494217" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of canakinumab in the cryopyrin-associated periodic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34001647" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from theβ-Confident Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24906637" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134734" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33158880" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808830" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Brief Report: Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin-Associated Periodic Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28482054" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29858461" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Flare of a Cryopyrin-associated Periodic Syndrome Following Vaccination with Neisseria Meningitidis Polysaccharides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29366613" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Keratoendotheliitis Fugax Hereditaria: A Novel Cryopyrin-Associated Periodic Syndrome Caused by a Mutation in the Nucleotide-Binding Domain, Leucine-Rich Repeat Family, Pyrin Domain-Containing 3 (NLRP3) Gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740632" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical Spectrum and Geographic Distribution of Keratitis Fugax Hereditaria Caused by the Pathogenic Variant c.61G&gt;C in NLRP3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494218" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19494219" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : An autoinflammatory disease due to homozygous deletion of the IL1RN locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431714" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431772" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431779" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814674" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
